Study of Efficacy, Safety and Tolerability of ACZ885 (Canakinumab) in Patients With Pulmonary Sarcoidosis

NCT02888080 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

40

Enrollment

INDUSTRY

Sponsor class

Conditions

Pulmonary Sarcoidosis

Interventions

DRUG: ACZ885
DRUG: Placebo

Sponsor

Novartis Pharmaceuticals